Acute myocardial infarction in young adults with chronic kidney disease. Issue 7 (9th August 2022)

• Record Type: Journal Article
• Authors: Gyurjian, Karo; Schweis, Franz; Patel, Sej; Hammershaimb, Bryant; Chiu, Sarah; Nadadur, Malini; Chen, Aiyu; Wu, Yi-Lin; Lee, Ming-Sum
• Is Part Of: Coronary artery disease. Volume 33:Issue 7(2022)
• Page Start: 553
• Page End: 558
• Publication Date: 2022-08-09
• Subjects: chronic kidney disease -- myocardial infarction -- young adults; Coronary heart disease -- Periodicals; Coronary Disease -- Indexes; Coronary Disease -- Periodicals; 616.123005
• DOI: 10.1097/MCA.0000000000001179
• Languages: English
• ISSNs: 0954-6928

Abstract

Abstract : Objective: The goal of this study was to evaluate the prevalence of chronic kidney disease (CKD) in young patients with acute myocardial infarction (AMI) and to report their characteristics and clinical outcomes. Background: Underlying renal dysfunction is a risk factor for poor cardiovascular outcomes in older patients. The implication of CKD in young patients with AMI is not well studied. Methods: This is a retrospective population-based cohort study of patients aged 18–50 who presented with AMI between 2006 and 2016. Medical records were reviewed to confirm diagnosis and to identify treatment and long-term outcomes. Cox regression models were used to evaluate the association of CKD with mortality. Results: Among 1753 young patients with type 1 AMI (median age 45 years, 85.3% male), CKD was present in 112 (6.8%) patients. A higher proportion of CKD patients had concomitant hypertension, hyperlipidemia, diabetes, and obesity. Use of statin and P2Y12 inhibitors post-AMI was lower in CKD patients. Over a median follow-up of 7.2 years, CKD was associated with higher all-cause mortality [hazard ratio (HR), 9.3; 95% CI, 6.3–13.8]. This association persisted after adjusting for demographics, comorbidities, and treatment (adjusted HR, 3.6; 95% CI, 2.2–6.0). Conclusion: Presence of CKD was associated with 3.6-fold higher mortality over a median follow-up of 7.2 years. A lower proportion of CKD patients were treated with statin therapy and P2Y12 inhibitors. These findings highlight the need for intensive risk factor modification and optimal use of guideline-directed medical therapies in this high-risk population.